Sun Pharmaceutical Industries Ltd. is arranging a $4 billion syndicated loan to replace part of the short-term bridge financing that backs its $11.75 billion acquisition of U.S. drugmaker Organon & Co., people familiar with the transaction said.
Five banks, Citibank, MUFG, Standard Chartered, BNP Paribas and DBS Bank, are expected to commit about $800 million each as lead arrangers and are finalizing terms, the people said. The loan would run five years and pay a margin of roughly 110 to 120 basis points over the Secured Overnight Financing Rate, which sits near 3.9%. It is expected to launch into senior syndication this week, with three or four more lenders joining before the facility is signed.
Taking out the bridge
Sun agreed in April to buy Organon, the Merck spinoff that sells health products for women, biosimilars and established brands, at an enterprise value of $11.75 billion. It funded the deal with an 18-month bridge loan from a group of 12 banks that included MUFG and State Bank of India. Replacing bridge money with longer-term debt is the usual next step once a buyer can see the path to closing, and it lowers the risk of having to refinance a large sum in a rush.
The company recently raised 7,816 crore rupees, or more than $800 million, by selling local non-convertible debentures priced at 8.05% for five years and 8.20% for seven years, and part of that money could also go toward repaying the bridge. Sun is also weighing more rupee debentures, equity and possibly dollar bonds as part of the broader financing plan, the people said. Sun Pharma and the banks declined to comment or did not respond.
What Sun is buying
Organon reported revenue of $6.2 billion in 2025 and adjusted operating profit of about $2 billion, a margin of roughly 31%, and revenue held steady above $3 billion in the first half of 2026, a ratings agency report said. Organon shareholders have approved the deal, which is expected to close in late 2026 or early 2027 as regulatory approvals arrive in different countries.
The loan would be among the largest syndicated financings for an Indian company this year and reflects how global banks are competing to fund outbound acquisitions by Indian groups as they buy assets in the U.S. and Europe.
Section: More Rock Hill SC business news
Rock Hill business profiles
Filed under: Rock Hill SC Business News